RANDOMIZED, OPEN-LABEL, PHASE 3 CLINICAL TRIAL OF N-803 + TISLELIZUMAB + DOCETAXEL VERSUS DOCETAXEL MONOTHERAPY IN PARTICIPANTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE ACQUIRED RESISTANCE TO IMMUNE CHECKPOINT INHIBITOR THERAPY
- Registry ID
- RESQ201A-NSCLC
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- IMMUNITYBIO, INC.
- Start date
- 2026-03-02
- Last update
- 2025-10-03
Conditions
- NON-SMALL CELL LUNG CANCER
Related clinical trials
- A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ADJUVANT INTISMERAN AUTOGENE PLUS SUBCUTANEOUS PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA MK-3475A) OR INTISMERAN AUTOGENE MONOTHERAPY VERSUS PLACEBO IN PARTICIPANTS WITH COMPLETELY RESECTED HIGH-RISK STAGE I NON-SMALL CELL LUNG CANCER (INTERPATH-014)
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF ADJUVANT MK-1084 PLUS SUBCUTANEOUS PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA (MK-3475A) VERSUS ADJUVANT PLACEBO PLUS MK-3475A IN PARTICIPANTS WITH COMPLETELY RESECTED STAGE IIA-IIIB (N2), KRAS G12C-MUTANT NON-SMALL CELL LUNG CANCER FOLLOWING RECEIPT OF EITHER NEOADJUVANT PEMBROLIZUMAB PLUS CHEMOTHERAPY OR ADJUVANT CHEMOTHERAPY (KANDLELIT-013)
- KONTRAST-R: AN OPEN-LABEL, MULTI-CENTER, ROLLOVER STUDY FOR PARTICIPANTS WHO HAVE BEEN PREVIOUSLY ENROLLED INTO A NOVARTIS-SPONSORED OPNURASIB (JDQ443) STUDY AND ARE CONTINUING TO BENEFIT FROM OPNURASIB AS A SINGLE AGENT OR IN COMBINATION WITH OTHER STUDY TREATMENTS
- AN INTERVENTIONAL PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
- A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MK-1084 IN COMBINATION WITH SUBCUTANEOUS PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA (MK-3475A) VERSUS MK-3475A IN COMBINATION WITH PEMETREXED/PLATINUM (CARBOPLATIN OR CISPLATIN) CHEMOTHERAPY AS FIRST-LINE TREATMENT OF PARTICIPANTS WITH KRAS G12C MUTANT, ADVANCED OR METASTATIC NONSQUAMOUS NSCLC (KANDLELIT-007)
- IZABRIGHT-LUNG01: A RANDOMIZED, OPEN-LABEL, PHASE 2/3 STUDY OF
IZALONTAMAB BRENGITECAN (BMS-986507) VERSUS PLATINUM-BASED CHEMOTHERAPY IN
PATIENTS WITH EGFR-MUTATED NON-SMALL CELL LUNG CANCER AND DISEASE
PROGRESSION ON EGFR TYROSINE KINASE INHIBITOR THERAPY
View on source registry